Merrimack Pharmaceuticals Inc  

(Public, NASDAQ:MACK)   Watch this stock  
Find more results for MACK
+0.09 (2.04%)
Apr 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.31 - 4.53
52 week 2.05 - 7.09
Open 4.45
Vol / Avg. 794,912.00/1.45M
Mkt cap 464.63M
P/E     -
Div/yield     -
EPS -1.32
Shares 103.25M
Beta     -
Inst. own 50%
May 13, 2014
Merrimack Pharmaceuticals Inc Annual Shareholder Meeting - 3:00PM EDT - Add to calendar
May 12, 2014
Q1 2014 Merrimack Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Mar 3, 2014
Merrimack Pharmaceuticals Inc at Cowen Health Care Conference
Feb 27, 2014
Q4 2013 Merrimack Pharmaceuticals Inc Earnings Conference Call
Feb 27, 2014
Q4 2013 Merrimack Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -413.50% -273.48%
Operating margin -361.01% -252.25%
EBITD margin - -246.83%
Return on average assets -62.28% -76.56%
Return on average equity - -
Employees 254 -
CDP Score - -


Suite B7201, One Kendall Square
United States - Map
+1-617-4411000 (Phone)
+1-617-4911386 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�s product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. The Company�s Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.

Officers and directors

Gary L. Crocker Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Robert J. Mulroy President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
William A. Sullivan Chief Financial Officer, Treasurer
Age: 42
Bio & Compensation  - Reuters
Clet M. Niyikiza Ph.D. Executive Vice President - Development
Age: 54
Bio & Compensation  - Reuters
Ulrik B. Nielsen Ph.D. Chief Scientific Officer, Senior Vice President
Age: 41
Bio & Compensation  - Reuters
Fazal R. Khan Ph.D. Senior Vice President - Manufacturing
Age: 63
Bio & Compensation  - Reuters
William M. McClements Senior Vice President - Corporate Operations
Age: 49
Bio & Compensation  - Reuters
Edward J. Stewart Senior Vice President and President, Merrimack Healthcare Solutions
Age: 42
Bio & Compensation  - Reuters
John Mendelsohn M.D. Director
Age: 76
Bio & Compensation  - Reuters
James H. Quigley Director
Bio & Compensation  - Reuters